Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes

[1]  F. W. Jamaluddin,et al.  Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. , 2014, Stem cells and development.

[2]  N. Kröger,et al.  Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Szer,et al.  Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  C. Schmoor,et al.  Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML , 2013, Bone Marrow Transplantation.

[5]  M. Horowitz,et al.  Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  N. Kröger,et al.  Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. , 2012, Blood.

[7]  E. Estey,et al.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  S. J. Kim,et al.  Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. , 2010, Transplantation proceedings.

[9]  M. Aker,et al.  A retrospective review of the outcome after second or subsequent allogeneic transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  G. Mufti,et al.  Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant , 2008, Bone Marrow Transplantation.

[11]  E. Shpall,et al.  Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation , 2007, Leukemia.

[12]  Sonali M. Smith,et al.  Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation , 2007, Bone Marrow Transplantation.

[13]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Storb,et al.  Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  J. Tuscano,et al.  367: Reduced intensity stem cell transplant (RIST) as salvage treatment for relapse following myeloablative allogeneic transplantation in adult acute myeloid leukemia , 2007 .

[16]  J. Tuscano,et al.  Reduced Intensity Stem Cell Transplant (RIST) as Salvage Treatment for Relapse Following Myeloablative Allogeneic Transplantation in Adult Acute Myeloid Leukemia. , 2006 .

[17]  J. Ritz,et al.  Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  J. Esteve,et al.  Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) , 2005, Leukemia.

[19]  E. Estey,et al.  Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia , 2005, Bone Marrow Transplantation.

[20]  M. Tallman,et al.  Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant , 2004, Bone Marrow Transplantation.

[21]  S. Wolff.  Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation , 2002, Bone Marrow Transplantation.

[22]  T. Braun,et al.  Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Craddock,et al.  Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG ± Ida) and second allogeneic stem cell transplant , 2001, British journal of haematology.

[24]  M. Labopin,et al.  Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Cahn,et al.  Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle (SFGM) , 2000, British journal of haematology.

[26]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[27]  K. Kishi,et al.  Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes , 1997, Bone Marrow Transplantation.

[28]  A. Bosi,et al.  Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) , 1997, Leukemia.

[29]  J. Radich,et al.  Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Gill,et al.  Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .

[31]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[32]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[33]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[34]  A. Dreher.  Modeling Survival Data Extending The Cox Model , 2016 .

[35]  S. Mielke,et al.  CHAPTER 40 – Management of relapse and minimal residual disease after stem cell allotransplantation , 2009 .

[36]  A. Barrett,et al.  Hematopoietic stem cell transplantation : in clinical practice , 2009 .

[37]  A. Verdeguer,et al.  Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON). , 2002, Haematologica.

[38]  M. Horowitz,et al.  Second HLA-identical sibling transplants for leukemia recurrence. , 1992, Bone marrow transplantation.

[39]  R Simon,et al.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.

[40]  D.,et al.  Regression Models and Life-Tables , 2022 .